Economic assessment on the management of chronic lymphocytic leukaemia.
In the last decade, several new promising treatments for chronic lymphocytic leukaemia (CLL) have been developed. Healthcare costs are increasing and new treatments tend to be very expensive; therefore, information about the cost effectiveness in treatments for CLL is urgently needed. The authors performed a literature review on the currently available economic evaluations on CLL treatments. A total of 65 articles were found, of which 11 could be included. These articles were evaluated on the basis of six methodological requirements for economic evaluations, enabling readers to judge the value of the studies. Only a small amount of information was available on the costs of CLL treatments. Future economic evaluations should be performed according to the methodological requirements for these studies, which should also be properly documented.
Goor
Kim M
KM
University Medical Centre Rotterdam, Erasmus MC, Institute for Medical Technology Assessment, PO Box 1738, 3000 DR Rotterdam, The Netherlands. k.goor@erasmusmc.nl
Schaafsma
M Ronald
MR
Huijgens
Peter C
PC
van Agthoven
Michel
M
D000465:Algorithms; D000911:Antibodies, Monoclonal / Q000191:economics / Q000627:therapeutic use; D000970:Antineoplastic Agents / Q000191:economics* / Q000627:therapeutic use; D002699:Chlorambucil / Q000191:economics / Q000627:therapeutic use; D003362:Cost-Benefit Analysis; D017048:Health Care Costs; D017721:Hospital Costs; D006801:Humans; D015451:Leukemia, Lymphocytic, Chronic, B-Cell / Q000188:drug therapy / Q000191:economics* / Q000532:radiotherapy; D008228:Lymphoma, Non-Hodgkin / Q000191:economics / Q000628:therapy; D016032:Randomized Controlled Trials as Topic; D033581:Stem Cell Transplantation / Q000191:economics*; D014740:Vidarabine / Q000031:analogs & derivatives / Q000191:economics / Q000627:therapeutic use
D000911:Antibodies, Monoclonal; D000970:Antineoplastic Agents; D002699:Chlorambucil; D014740:Vidarabine; C024352:fludarabine